Transcription of Public Assessment Report Mutual Recognition …
{{id}} {{{paragraph}}}
PAR Diclofenac Sodium 4% Spray Gel UK/H/0562-3/001/E01 1 public assessment report mutual recognition procedure Diclofenac Sodium 4% Spray Gel UK/H/0562-3/001/E01 Mika Pharma GmbH PAR Diclofenac Sodium 4% Spray Gel UK/H/0562-3/001/E01 2 Diclofenac Sodium 4% Spray Gel LAY SUMMARY Czech Republic, Poland, Slovak Republic, Estonia, Hungary, Latvia, Lithuania, Slovenia today granted Mika Pharma GmbH Marketing Authorisations (licences) for the medicinal products Diclofenac Sodium 4% Spray Gel (PL 18017/0001-2). These are prescription only medicines (POM) for the relief of acute pain and swelling affecting small or medium-sized joints and surrounding tissues. Diclofenac Sodium 4% Spray Gel contain the active ingredient diclofenac sodium, which belongs to a group of drugs called non-steroidal anti-inflammatory drugs (NSAID).
PAR Diclofenac Sodium 4% Spray Gel UK/H/0562-3/001/E01 1 Public Assessment Report Mutual Recognition Procedure Diclofenac Sodium 4% Spray Gel
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
{{id}} {{{paragraph}}}